Endocyte (NASDAQ:ECYT) is a small-cap biopharmaceutical company valued at $457 million with 71 employees located in West Lafayette, Indiana. The company specializes in small molecule drug conjugates (SMDC) with companion imaging diagnostics to target cancer cells ONLY in patients likely to benefit. You can read more about company from its website.
Unique Small Molecule Drug Conjugates (SMDC) + Imaging PlatformEndocyte's lead SMDC is called vintafolide (EC145), which consists of a targeting ligand, folate (or folic acid, an important vitamin nutrient for cell division), a linker/spacer region, and a drug payload, the microtubule destabilizing agent (which causes cell death, apoptosis) called desacetylvinblastine monohydrazide (DAVLBH). Vintafolide selectively binds to the folate receptor (FR) overexpressed on cancer cells, is...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|